New antibody treatment for severe asthma

Nucala (mepolizumab) can be prescribed as an add-on therapy for patients with severe refractory eosinophilic asthma.

The presence of eosinophils in the airway lumen has been shown to be predictive of loss of asthma control and a possible marker of disease severity. | SCIENCE PHOTO LIBRARY
The presence of eosinophils in the airway lumen has been shown to be predictive of loss of asthma control and a possible marker of disease severity. | SCIENCE PHOTO LIBRARY

Further information
View Nucala drug record
Summary of Product Characteristics
Manufacturer: GlaxoSmithKline

Mepolizumab is a humanised antibody that targets interleukin-5 (IL-5), the major cytokine responsible for eosinophil regulation. Mepolizumab prevents IL-5 from binding to the receptor on the eosinophil cell surface, inhibiting IL-5 signalling and reducing the production and survival of eosinophils. 

Exacerbations

Three double-blind, randomised controlled trials (DREAMMENSA and SIRIUS) found mepolizumab to be more effective than placebo in reducing the rate of exacerbations in patients with severe asthma. In addition, patients receiving mepolizumab experienced greater reductions in their daily maintenance oral corticosteroid dose than patients receiving placebo, while maintaining asthma control.

Administration

Nucala is administered by a healthcare professional via subcutaneous injection into the upper arm, thigh or abdomen every four weeks.

Headaches were reported as the most frequently occurring adverse effect.


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.